BridGene Biosciences

What BridGene Biosciences does

BridGene Biosciences is a clinical-stage biotechnology company that develops covalent small molecule therapeutics for protein targets historically considered undruggable, including transcription factors, E3 ligases, splicing factors, and disease-driven mutant proteins. The company's core technology is the proprietary IMTAC chemoproteomics platform, which combines proteome-wide live-cell covalent screening (having identified 5,000+ covalent binding targets across the human proteome), target-focused live-cell screening (delivering validated hits in 4-6 months at ~5,000 compounds per month), and AI-powered virtual screening across 170B+ virtual compounds. A proprietary library of 10,000+ paired covalent small molecules — each pair comprising a tagged capture molecule and an untagged competitor — supports warheads targeting multiple amino acids beyond cysteine, including lysine and tyrosine.

The company operates a partnership-driven business model, generating revenue through upfront payments, preclinical and clinical milestone payments, and tiered royalties on net sales from multi-target collaborations with enterprise pharmaceutical companies. Active partnerships include two deals with Takeda (Immunology & Neurology for $770M and Neurodegenerative Disease for $500M in potential total value) and two deals with Galapagos (Oncology for $700M and SMARCA2 PROTAC for $159M), representing over $2.1 billion in aggregate potential deal value. BridGene also develops a proprietary pipeline, with lead clinical candidate BGC-515 (a covalent TEAD inhibitor for solid tumors) advancing toward Phase 2 trials, and supports covalent PROTAC degrader programs.

BridGene is a private, venture-backed company headquartered in San Jose, California with a secondary office in Suzhou, China. The company was founded in 2016, has 11-50 employees, and has raised approximately $78.5 million across three equity financing rounds (Series A $12M in 2021, Series B $38.5M in 2022, Series B+ $28M in 2025). Key institutional investors include Bayland Capital, Wedo Venture Partners, GTJA Investment Group, and Proxima Ventures. The company is led by Co-Founder & CEO Ping Cao, Ph.D. and has appointed Nobel Laureate Bruce A. Beutler, M.D. to its Scientific Advisory Board.

Name

BridGene Biosciences

Legal name

BridGene Biosciences

Website

https://bridgenebio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

BridGene Biosciences is a clinical-stage biotechnology company that uses its proprietary IMTAC chemoproteomics platform to discover covalent small molecule drugs targeting traditionally undruggable proteins, serving enterprise pharmaceutical partners through licensing, co-development, and milestone-based collaboration agreements.

Ownership category

akta.pro rank

Product category

Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Chemoproteomics platform
• Covalent drug discovery
• Small molecule therapeutics
• Covalent inhibitor screening
• Precision oncology drugs

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Strategic Partnership Payments: Revenue from pharmaceutical partnerships including upfront payments, preclinical milestones, clinical milestones, and commercial milestones. Also includes tiered royalties on net sales of any products resulting from collaborations. Examples: Takeda $770M and $500M deals, Galapagos $700M and $159M deals.
2. Research Collaboration Funding: Direct research funding from partners for specific drug discovery programs targeting oncology, immunology, neurology, and neurodegeneration using the IMTAC platform.
3. Pipeline Drug Development: Development and potential commercialization of proprietary pipeline candidates including BGC-515, a covalent TEAD inhibitor in clinical trials for solid tumors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BridGene Biosciences develops and commercializes covalent small molecule therapeutics and drug discovery services through its proprietary IMTAC chemoproteomics platform, which performs proteome-wide and target-focused live-cell covalent screening backed by a 10,000+ pair covalent compound library. The platform enables discovery of covalent ligands for traditionally undruggable targets (transcription factors, E3 ligases, splicing factors) and supports both proprietary pipeline assets (e.g., BGC-515 covalent TEAD inhibitor in clinical development for solid tumors) and partnered programs with major pharmaceutical companies.

Product overview

BridGene Biosciences operates as a biotechnology company with an integrated drug discovery platform centered on its proprietary IMTAC™ chemoproteomics technology. The platform consists of three interconnected screening approaches: (1) IMTAC™ Live Cell Proteome-Wide Screening for discovering targets across 5,000+ proteins, (2) IMTAC™ Live Cell Target-Focused Screening for target-specific hit identification within 4-6 months, and (3) IMTAC™ Virtual Screening (AI) combining generative AI with physics-based docking across 170B+ virtual compounds. These platforms are powered by a Covalent Small Molecule Library of 10,000+ drug-like compounds and support the company's lead clinical candidate BGC-515, a covalent TEAD inhibitor for solid tumors, as well as PROTAC development programs in partnership with Galapagos.

Differentiator

Problem solved

Functional benefit

Products and services

• IMTAC Platform Proprietary chemoproteomics drug discovery platform that combines live-cell covalent screening (proteome-wide and target-focused) with AI- and physics-based covalent virtual screening to discover small molecule drugs against historically undruggable proteins including transcription factors, E3 ligases, splicing factors, and mutation-driven targets. Licensed to enterprise pharmaceutical and biotechnology partners through strategic collaborations and used to advance BridGene's internal pipeline.
• BGC-515 Lead clinical pipeline candidate: a covalent small molecule inhibitor of TEAD (TEA domain transcription factor), discovered via the IMTAC chemoproteomics platform and in clinical development for solid tumors. Represents BridGene's proprietary therapeutic asset arising from its platform.

Quantifiable outcome

• 5,000+ covalent binding targets identified across human proteome
• +3 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• TakedaflagshipStrategic or Co-development Partner · 25 February 2025BridGene and Takeda have entered a strategic partnership focused on developing covalent degraders targeting oncology using the IMTAC platform. The Immunology & Neurology Small Molecule Discovery Collaboration includes multiple targets with potential upfront and preclinical milestone payments of $46 million, plus clinical and commercial milestones totaling up to $770 million, along with tiered royalties on net sales.
• GalapagoscoreStrategic or Co-development Partner · 1 August 2024SMARCA2 PROTAC Development Collaboration combining BridGene's PROTAC discovery engine with Galapagos' expertise in selective ATPase small molecules. Goal is to advance a selective oral PROTAC for precision oncology into preclinical candidate. Total deal value up to $159 million including upfront, preclinical, clinical, and commercial milestones plus royalties.
• GalapagosflagshipStrategic or Co-development Partner · 3 January 2024Oncology Drug Discovery Collaboration focused on discovering novel small molecules using IMTAC platform for targets named by Galapagos. BridGene receives up to $27 million in upfront and preclinical research milestone payments, plus more than $700 million in clinical and commercial milestones, and tiered royalties on net sales.
• TakedacoreStrategic or Co-development Partner · 30 March 2021Neurodegenerative Disease Drug Discovery Collaboration focused on traditionally 'undruggable' targets using IMTAC platform. Takeda receives exclusive license to research, develop, and commercialize drug candidates. BridGene eligible for preclinical, clinical, and commercial milestone payments exceeding $500 million, plus royalties from future sales.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Frontier Medicines: Frontier Medicines uses chemoproteomics and covalent chemistry to drug challenging targets, mirroring BridGene's IMTAC-based approach. The companies overlap in technology stack, target classes (including E3 ligases), and partnership-driven model.
• Arvinas: Arvinas is a clinical-stage targeted protein degradation company pioneering PROTAC degraders, overlapping with BridGene's PROTAC discovery engine and covalent chemistry approach, particularly relevant given the Galapagos SMARCA2 collaboration.
• Nurix Therapeutics: Nurix is a clinical-stage targeted protein degradation company developing both molecular glues and PROTACs. Its ligase-based degrader approach is complementary/competitive with BridGene's covalent PROTAC engine for oncology and immunology indications.
• Foghorn Therapeutics: Foghorn focuses on chromatin biology and transcription factors, classes of targets BridGene explicitly nominates through its IMTAC platform. Both companies pursue small-molecule approaches to historically undruggable targets in oncology.
• Kymera Therapeutics: Kymera is a clinical-stage biotech developing targeted protein degraders with a focus on immunology and oncology. It directly overlaps with BridGene's covalent PROTAC and degrader programs in therapeutic area and modality.
• Vividion Therapeutics: Vividion is a chemoproteomics-driven covalent drug discovery company that uses chemical proteomics to identify ligands for traditionally undruggable targets. It is the closest direct comparable to BridGene's IMTAC platform in both technology and partnership-driven business model.

Emerging players

• Scorpion Therapeutics: Scorpion develops precision oncology drugs against high-value but difficult targets. While more focused on best-in-class kinase and transcription factor inhibitors, it overlaps with BridGene's oncology pipeline targeting traditionally undruggable proteins.
• Revolution Medicines: Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies, including covalent inhibitors, against difficult targets like SHP2 and RAS. It is comparable to BridGene on oncology focus and covalent chemistry, though with a more kinase-centric pipeline.

Others

• Schrödinger: Schrödinger provides physics-based computational drug discovery software and AI-enabled molecular design. Its platform competes with elements of BridGene's AI + physics-powered virtual screening component, though Schrödinger is software-first rather than wet-lab-driven.

Broad incumbents

• Recursion: Recursion is a larger, publicly listed AI-driven drug discovery company combining high-throughput biology with machine learning. It overlaps thematically with BridGene's AI-powered screening approach but operates at significantly greater scale and across a broader target space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/bridgene-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BridGene Biosciences